[ad_1] SAN FRANCISCO and SUZHOU, China, November 15, 2020 / PRNewswire / – Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and markets high-quality medicines for the treatment of oncological, metabolic, autoimmune and other major diseases, announces that the results of Phase Clinical I The …
Read More »Innovent announces Phase I clinical trial results of IBI302, a first-class anti-VEGF and anti-complement ophthalmic recombinant human bi-specific fusion protein for age-related neovascular macular degeneration at 2020 AAO
